









Markets
/
Stocks
/
nasdaq-poai
/

Predictive Oncology Inc

POAI

1.010USD

+0.023+2.31%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

9.69MMarket Cap

LossP/E TTM



Predictive Oncology Inc

1.010

+0.023+2.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

290 / 506

Overall Ranking

495 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

3.000

Target Price

+251.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.62M.

Undervalued

The company’s latest PE is -0.86, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 299.51K shares, decreasing 49.08% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 71.31K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.30, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 2.68K, representing a year-over-year decrease of 99.04%, while its net profit experienced a year-over-year decrease of 34.92%.

Score

Industry at a Glance

Previous score

5.30

Change



Financials

4.11

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.23

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.84, which is -64.67% below the recent high of -0.30 and 6.35% above the recent low of -0.78.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 290/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Predictive Oncology Inc is 3.00, with a high of 3.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.82, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.09 and the support level at 0.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.82

Change

0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.008

Buy

RSI(14)

61.972

Neutral

STOCH(KDJ)(9,3,3)

58.592

Neutral

ATR(14)

0.078

High Vlolatility

CCI(14)

94.243

Neutral

Williams %R

30.435

Buy

TRIX(12,20)

0.651

Sell

StochRSI(14)

70.181

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.990

Buy

MA10

0.978

Buy

MA20

0.942

Buy

MA50

0.860

Buy

MA100

0.911

Buy

MA200

1.049

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 2.93%, representing a quarter-over-quarter decrease of 12.58%. The largest institutional shareholder is The Vanguard, holding a total of 71.31K shares, representing 0.62% of shares outstanding, with 41.71% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Vennare (Raymond F)

7.12K

Nuzum (Charles Lee Sr)

29.91K

+7.22%

St Clair (Gregory Sr)

21.20K

+6.70%

Chung-Welch (Nancy)

19.31K

+11.64%

Handley (Daniel E)

17.02K

+10.69%

Hawryluk (Matthew)

9.49K

Rao (Veena)

9.12K

The Vanguard Group, Inc.

Star Investors

71.31K

Geode Capital Management, L.L.C.

62.93K

+22.90%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.